Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Soared Today

By Joe Tenebruso - Jan 25, 2021 at 7:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's COVID-19 vaccine appears to protect against several new coronavirus mutations.

What happened

Shares of Moderna (MRNA -4.97%) jumped 12.2% on Monday after the biotechnology company said its COVID-19 vaccine provides protection against new coronavirus strains first identified in the U.K. and South Africa. 

So what 

Scientists have discovered several new variants of the novel coronavirus that are more contagious -- and potentially more dangerous -- than previous versions. Doctors, in turn, have questioned whether Moderna's vaccine would be effective against the new strains. 

Moderna said on Monday that its vaccine did provide protection against all the strains tested, including those found in the U.K. and South Africa, in a study conducted in collaboration with the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID). 

Researchers working in a laboratory.

Moderna is ramping up its coronavirus vaccine research. Image source: Getty Images.

However, Moderna saw a sixfold reduction in neutralizing antibodies with the strain from South Africa. Though they remained above levels that are believed to guard people against the disease, Moderna will test whether a booster dose of its vaccine could provide additional protection.

"As we seek to defeat the COVID-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves," Moderna CEO Stephane Bancel said in a press release.

Now what

Moderna intends to begin its vaccine booster studies in March. The company hopes to have results back before the autumn, when viral infection rates tend to rise. "The thing we want to be ready for is the fall," Bancel told Yahoo! Finance. "We don't have to go again through a dreadful winter like we're going through now." 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$136.25 (-4.97%) $-7.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.